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www.jacctctabstracts2014com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMreplacement in high operative risk patients. The currently most widely used valves are
Edwards SAPIEN XT and Medtronic CoreValve.
Methods: We analyzed data of 424 consecutive patients undergoing trans-femoral
TAVI at the Tel Aviv Medical Center, and performed a comparison between the two
bioprostheses regarding pre-procedural patient’s characteristics, procedural data and
1 year post-procedural clinical outcome.
Results: CoreValve and the Edwards SAPIEN prostheses were implanted in 320 and
104 patients, respectively. CoreValve patients were older (835 vs. 817 years,
p¼0.026), with lower estimated glomerular ﬁltration rate (6018 vs. 6620 ml/min/
1.73m2, p¼0.009), higher EuroSCORE (25 14 vs. 20 13 %, p¼0.015) and a
smaller pre-procedural aortic valve area (0.69 0.18 vs. 0.74 0.19 cm2, p¼0.035).
No other differences regarding patient’s characteristics were observed. Compared to
TAVI with Edwards prosthesis, Corevalve procedures had shorter ﬂuoroscopy
time (16.46 vs. 17.55 minutes, p¼0.02), higher patient’s cumulative radiation
dose (1477755 vs. 1197591 Gy, p< 0.001), and less contrast media (14340 vs.
15740 ml, p¼0.001). Device success was similar among the two valves (95 vs. 96%,
p¼0.57). Mortality (in hospital and after 1 year) was similar among the valves
implanted (2.5 vs. 2.9%, p¼0.83, and 15.7 vs. 19%, p¼0.54). CoreValve patients had
higher rates of permanent pacemaker implantation (24.4 vs. 11.5%, p¼0.005), and
post-procedural blood transfusion (40 vs. 25%, p¼0.014). No difference was observed
regarding vascular complication (18 vs. 21%, p¼0.49), stroke (1.3 vs. 1.9%, p¼0.61),
moderate or severe paravalvular leak (2 vs. 2.6%, p¼0.766), or acute kidney injury of
any stage (13.8 vs. 19.6%, p¼0.15).
Conclusions: Despite differences in patient’s and procedural characteristics between
CoreValve and Edwards Sapiens TAVI, device success and mortality rates were
similar.
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Background: Transcatheter aortic valve replacement (TAVR) is primarily performed
in non-operable and high-risk surgical patients, including those of advanced age. The
clinical proﬁles, procedural characteristics, and outcomes of nonagenarians undergo-
ing TAVI have not been reported.
Methods: We evaluated 72 patients >90 years old with severe symptomatic aortic
stenosis undergoing TAVR. Baseline characteristics at time of TAVR were collected
which include co-existing conditions as well as periprocedural ﬁndings and Valve
Academic Research Consortium-2 (VARC-2) complications. Death at 30-days and 1-
year were also evaluated.
Results: The cohort represents 47% males (84% Caucasian; age 932 years) with
mean Society of Thoracic Surgeons (STS) and EuroSCORE of 12.34.6 and
26.822.5, respectively. Non-operable indication was 55%, and the majority received
a balloon expandable valve (85%). While hypertension was very prevalent (92%),
other STS risk factors were considerably lower than anticipated: diabetes (21%),
COPD (17%; 4.5% severe), cerebral vascular disease (19%), peripheral arterial disease
(27%), prior myocardial infarction (16%), prior coronary artery bypass (14%), or
glomerular ﬁltration rate < 60 mL/min (50%). Mean body mass index was
23.93.7kg/m2. Transfemoral procedural duration was 111.3  48 minutes with
VARC-2 device success of 95.9%. Post-TAVR length of stay was 86 days. High
rates of major vascular complications were present and a large proportion of deaths
occurred early (table).Adverse Events Following TAVR
In-Hospital Outcomes
VARC-2 major vascular complication 15.5%
VARC-2 major bleed 2.7%
Ischemic stroke 2.7%
Pacemaker implantation 5.5%
Worsening heart failure 30.1%
Moderate or severe aortic insufﬁciency 1.6%
Death 6.8%
Death at 30-days 11.0%
Death at 1-year 26.0%
JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/VaConclusions: Despite high rates of 30-day mortality, survival at 1-year is similar to
patients a decade younger, likely the result of a favorable pre-procedural health history
in this cohort. Thus, TAVR should not be withheld from nonagenarians.
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Background: Aortic valve stenosis (AVS) can be complicated by bleeding associated
with acquired type 2A von Willebrand syndrome. The association of AVS and
gastrointestinal bleeding from angiodysplasia is deﬁned as Heyde’s syndrome. We
sought to evaluate the impact of TAVI on primary hemostasis disorders and to assess
its effectiveness to treat Heyde’s syndrome.
Methods: We prospectively enrolled 49 consecutive patients with severe AVS
addressed for TAVI in our institution. Biological primary hemostasis parameters were
assessed at baseline and one week after the procedure.
Results: We identiﬁed 1 (2%) patient with Heyde’s syndrome, and 11 patients
(22.4%) with a ratio vWF:CB/vWF:Ag under 0.7, compatible with type 2A vWF
syndrome. At baseline, a signiﬁcant link between vWF abnormalities and the severity
of AVS was evidenced: mean aortic transvalvular gradient was negatively correlated
with the levels of vWF antigen (vWF:Ag) (r¼ -0.29, p< 0.05), vWF ristocetin
cofactor activity (vWF:RCo) (r¼-0.402, p¼0.006) and vWF collagen-binding activity
(vWF:CB) (r¼-0.441, p¼0.005). One week after the procedure, a signiﬁcant increase
of vWF:Ag, vWF:RCo, and vWF:CB was evidenced in the whole cohort (respectively
3.32 vs 2.29 IU/mL, p< 0.001 ; 2.98 vs 1.86 IU/mL, p< 0.001 ; 3.16 vs 2.16 IU/mL,
p< 0.001). Patients with pre-TAVI vWF abnormalities consistent with a type 2A vWF
syndrome preferentially improved their vWF function with respect to patients with a
normal ratio (relative increase of vWF:CB of 63.8% vs 3.5%).
Conclusions: Primary hemostasis parameters involving vWF are improved after
TAVI, especially in patients with preexisting abnormalities consistent with acquired
type 2A von Willebrand syndrome. Moreover, our observations, although limited to a
small single-center study, suggest that Heyde’s syndrome can be cured by TAVI.
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Background: We sought to identify the prevalence and prognostic impact of left
ventricular reverse remodeling (LVRR) in a non-selected high-risk patient population
with severe aortic stenosis undergoing transcatheter aortic valve implantation (TAVI).
Methods: Two hundred thirty-nine consecutive patients undergoing TAVI were
enrolled in our retrospective analysis between November 2008 and December 2013.
LVRR was deﬁned as a left ventricular ejection fraction increase of 10 U or a left
ventricular ejection fraction of 50%, a decrease in indexed left ventricular end-
diastolic diameter of 10% or indexed left ventricular end-diastolic diameter of 33
mm/m2, and an interventricular septum thickness 11 mm at 7258 days.
Results: LVRR was found in 44 patients (18%). When added to a prognostic baseline
model including age, diabetes, baseline left ventricular ejection fraction and aortic valve
area, emerged as independent predictor of long-term (1.71.4 years)mortality (HR0.28,
95%CI 0.13-0.62, p¼0.002), along with diabetes (HR 4.6, 95%CI 1.5-13.7, p¼0.006).
Conclusions: Early LVRR is a predictor of long-term clinical outcome.
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Background: Trans-catheter heart valve implantation is a therapeutic option for the
treatment of patients with bioprosthetic valve failure. We aim to describe our expe-
rience using this technique in the treatment of degenerated mitral, aortic and tricuspid
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